|
|
| | Soluble Epoxide Hydrolase (FL) Polyclonal Antibody Basic information |
| | Soluble Epoxide Hydrolase (FL) Polyclonal Antibody Chemical Properties |
| | Soluble Epoxide Hydrolase (FL) Polyclonal Antibody Usage And Synthesis |
| Description | Soluble epoxide hydrolase (sEH) is a member of the α/β-hydrolase fold enzyme family that catalyzes the hydrolysis of bioactive fatty acid epoxides to inactive vicinal diols. It is a homodimer in which each subunit is composed of two domains, a C-terminal epoxide hydrolase domain and an N-terminal phosphatase domain. sEH is localized to the cytoplasm or to peroxisomes in a tissue specific manner and is found in various tissues, including skin, lung, uterus, kidney, brain, and myocardium. sEH is also expressed in the vasculature and inhibition of sEH attenuates pathogenic vascular remodeling and hypertension via preservation of cardioprotective epoxyeicosatrienoic acids (EETs) in rat models of atherosclerosis and hypertension, respectively. Inhibition of sEH also has a protective role in various diseases including inflammatory bowel disease, osteoarthritis, seizure, stroke, and Alzheimer’s disease, as well as in various chronic pain states. Cayman’s Soluble Epoxide Hydrolase (FL) Polyclonal Antibody can be used for Western blot applications. The antibody recognizes sEH at 64 kDa from human and murine samples. | | References | [1] TODD R. HARRIS Bruce D H. Soluble epoxide hydrolase: Gene structure, expression and deletion[J]. Gene, 2013, 526 2: Pages 61-74. DOI: 10.1016/j.gene.2013.05.008
[2] ANNETTE CRONIN. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100 4: 1552-1557. DOI: 10.1073/pnas.0437829100
[3] NIPAVAN CHIAMVIMONVAT. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.[J]. Journal of Cardiovascular Pharmacology, 2007, 50 3: 225-237. DOI: 10.1097/fjc.0b013e3181506445
[4] AHMED E ENAYETALLAH. Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues.[J]. Journal of Histochemistry & Cytochemistry, 2006, 54 3: 329-335. DOI: 10.1369/jhc.5a6808.2005
[5] MICHELLE FLORES DOMINGUES. Soluble Epoxide Hydrolase and Brain Cholesterol Metabolism.[J]. Frontiers in Molecular Neuroscience, 2020: 325. DOI: 10.3389/fnmol.2019.00325
[6] A N SIMPKINS. Soluble epoxide hydrolase inhibition modulates vascular remodeling.[J]. ACS Applied Energy Materials, 2010: H795-806. DOI: 10.1152/ajpheart.00543.2009
[7] KAREN M. WAGNER . Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases[J]. Pharmacology & Therapeutics, 2017, 180: Pages 62-76. DOI: 10.1016/j.pharmthera.2017.06.006 |
| | Soluble Epoxide Hydrolase (FL) Polyclonal Antibody Preparation Products And Raw materials |
|